Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dysarthria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Dysarthria. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-005475-41 Sponsor Protocol Number: MLX Start Date*: 2014-11-05
    Sponsor Name:UZ Brussel
    Full Title: Sulfamethoxazole treatment of primary PREPL deficiency
    Medical condition: Hypotonia-cystinuria syndrome and isolated PREPL deficiency.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005371-34 Sponsor Protocol Number: 2 39 00240 133 Start Date*: 2008-03-18
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study.
    Medical condition: Out patient suffering from friedreich ataxia aged from 12 to 20 years
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001235-20 Sponsor Protocol Number: 14.0189 Start Date*: 2015-06-05
    Sponsor Name:St George's University of London
    Full Title: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease
    Medical condition: PARTICIPANTS WITH EVIDENCE OF CEREBRAL SMALL VESSEL DISEASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003242-34 Sponsor Protocol Number: 67103 Start Date*: 2005-11-21
    Sponsor Name:National Institutes of Neurological Disorders: Stroke
    Full Title: Secondary Prevention of Small Subcortical Strokes
    Medical condition: Secondary prevention of small subcortical strokes
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063751 Ministroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000896-26 Sponsor Protocol Number: ETLAS Start Date*: 2016-05-19
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Effect of Tadalafil on cerebral large arteries in stroke patients.
    Medical condition: Stroke and small vessel disease.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10070879 Cerebral small vessel ischemic disease LLT
    19.0 10029205 - Nervous system disorders 10076994 Lacunar stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001983-39 Sponsor Protocol Number: PHALS Start Date*: 2017-09-28
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled double blind randomized trial to investigate the efficacy and safety of the combination of Penicillin G / Hydrocortisone treatment in ALS patients (PHALS).
    Medical condition: Patients suffereing from Amytrophic Lateral Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006224-40 Sponsor Protocol Number: AxGD Start Date*: Information not available in EudraCT
    Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka"
    Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p...
    Medical condition: Gaucher disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005317-37 Sponsor Protocol Number: THR-2010-01 Start Date*: 2012-06-14
    Sponsor Name:Thrombotech Ltd.
    Full Title: Double blind, placebo controlled, escalating single-dose, pilot study to assess the safety of THR-18 when administered to patients suffering acute ischemic stroke and treated with tPA
    Medical condition: Acute isquemic stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018157-23 Sponsor Protocol Number: D0490C00014 Start Date*: 2010-11-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ...
    Medical condition: Multiple system atrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064060 Multiple system atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000137-13 Sponsor Protocol Number: ORARIALS-01 Start Date*: 2018-10-05
    Sponsor Name:Orphazyme A/S
    Full Title: A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005312-26 Sponsor Protocol Number: FACEG Start Date*: 2013-03-18
    Sponsor Name:Hospital of the University of Munich, Grosshadern
    Full Title: Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder
    Medical condition: cerebellar gait disorder, cerebellar ataxia, sensorimotor adaption and ocular motor disorders, postural sway, dysarthria
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10008025 Cerebellar ataxia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001075-35 Sponsor Protocol Number: TG-M-003 Start Date*: 2007-04-12
    Sponsor Name:ThromboGenics Ltd.
    Full Title: AN OPEN-LABEL CLINICAL TRIAL OF INTRA-ARTERIAL MICROPLASMIN ADMINISTRATION IN PATIENTS WITH ACUTE INTRACRANIAL VERTEBROBASILAR ARTERY OCCLUSION
    Medical condition: ACUTE INTRACRANIAL VERTEBROBASILAR ARTERY OCCLUSION RESULTING IN ACUTE ISCHEMIC STROKE
    Disease: Version SOC Term Classification Code Term Level
    8.1 10048963 Basilar artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001185-91 Sponsor Protocol Number: FMPS–30094 Start Date*: 2008-06-06
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Central randomized, double-blind, crossover, multicenter clinical trial of Betametasone and placebo in children with ataxia teleangectasia
    Medical condition: ataxia teleangectasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 Nervous system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003613-19 Sponsor Protocol Number: APHP210303 Start Date*: 2021-12-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS
    Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004619-30 Sponsor Protocol Number: ALXN1210-ALS-308 Start Date*: 2020-09-14
    Sponsor Name:Alexion Pharmaceuticals
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotroph...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS), motor neuron disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004505-16 Sponsor Protocol Number: CONVINCE Start Date*: 2016-08-08
    Sponsor Name:University College Dublin
    Full Title: CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke
    Medical condition: The prevention of recurrent stroke and coronary events (fatal and non- fatal) after ischaemic stroke and transient ischaemic attack (TIA) not caused by cardiac embolism or other causes unrelated to...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044376 Transient cerebrovascular events HLT
    20.0 100000004866 10008205 Cerebrovascular embolism and thrombosis HLT
    22.1 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10029205 - Nervous system disorders 10007962 Central nervous system vascular disorders NEC HLT
    20.0 10029205 - Nervous system disorders 10007963 Central nervous system vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) DK (Completed) PT (Completed) BE (Completed) LT (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002754-36 Sponsor Protocol Number: 3119002 Start Date*: 2018-05-08
    Sponsor Name:Orion Corporation
    Full Title: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) BE (Completed) FI (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005194-37 Sponsor Protocol Number: CT-ORZY-NPC-001 Start Date*: 2015-10-19
    Sponsor Name:Orphazyme ApS
    Full Title: A prospective non-therapeutic study in patients diagnosed with Niemann-Pick disease type C in order to characterise the individual patient disease profile and historic signo-symptomatology progress...
    Medical condition: Niemann-Pick disease - type C
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10029403 Niemann-Pick disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-000858-18 Sponsor Protocol Number: 281102 Start Date*: 2017-09-12
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 (rADAMTS13) in the pro...
    Medical condition: severe congenital thrombotic thrombocytopenic purpura (cTTP, Upshaw-Schulman Syndrome [USS], hereditary thrombotic thrombocytopenic purpura [hTTP])
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10043562 Thrombocytopenic purpura, thrombotic LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) AT (Completed) FR (Completed) IT (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004567-21 Sponsor Protocol Number: 3119001 Start Date*: 2015-06-05
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension
    Medical condition: Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:55:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA